Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant rise in the number of TC cases has been observed for the past few decades. TCs are one of the most frequent tumors in younger adults, especially in women, therefore early diagnosis and effective therapy are espec...
Guardado en:
Autores principales: | Maciej Ratajczak, Damian Gaweł, Marlena Godlewska |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ea69f592d85146938c7e29fb96bf3eaf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Analysis of NIS Plasma Membrane Interactors Discloses Key Regulation by a SRC/RAC1/PAK1/PIP5K/EZRIN Pathway with Potential Implications for Radioiodine Re-Sensitization Therapy in Thyroid Cancer
por: Márcia Faria, et al.
Publicado: (2021) -
MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells
por: Márcia Faria, et al.
Publicado: (2021) -
Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
por: Ke Y, et al.
Publicado: (2018) -
Targeted Therapies in Cancer: To Be or Not to Be, Selective
por: Skye Montoya, et al.
Publicado: (2021) -
Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021)